A NOVEL APPROACH TO TREATING MEDICALLY REFRACTORY NEUROLOGICAL CONDITIONS

Over 9.0 million patients in the US and EU are not effectively treated today with oral medications for the diseases of depression and epilepsy ("refractory patients").  This represents a significant unmet need.  Competitive therapies in development (including inhaled, long acting and transdermal medications) do not offer the combination of lower systemic side effects and improved patient compliance necessary to make a significant advancement in the treatment of these diseases. 

IMPLANTABLE INFUSION PUMP AS A DIRECT DELIVERY SYSTEM FOR TREATMENT OF BRAIN DISORDERS

Implantable pumps for the nervous system have more than 20 years of safety data and physician experience and are being used to treat over 85,000 people today for spinal related diseases of pain and spasticity.  Advantages of direct delivery to the CSF include the ability to limit systemic exposure while treating the brain, simplifying patient compliance, and the ability to administer drugs with greater precision and control (including constant drug dosing).  Sierra helps refractory patients with neurologic and psychiatric disorders receive medications that are highly effective through an implantable drug technology that possesses all of these advantages. 

REFORMULATION OF APPROVED DRUGS